Drugs and Devices

FDA approves treatments for irritable bowel syndrome

On May 27, the U.S. Food and Drug Administration (FDA) approved Viberzi (eluxadoline) and Xifaxan (rifaximin) for irritable bowel syndrome with diarrhea in adult men and women. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares